CDK2 and colorectal cancer: These findings contribute to the structure-based rational drug design pipeline, facilitating the development of selective and potent CDK2 inhibitors as potential therapeutic agents, particularly for the treatment of CDK2-driven malignancies such as colorectal cancer.